Note: Page numbers of article titles are in boldface type. A C a-aminobutyric acid, carbon-labeled, 94 ABCD(E)s, of melanoma, 2 Acral-lentiginous melanoma, 3 Adrenal glands, metastasis to, structural imaging for, 44 Advanced melanoma PET/CT for, 27 35 structural imaging for, 37 54 Age, melanoma prognosis and, 19 Amelanotic melanoma, 3 American Joint Committee on Cancer TNM classification, 3 5, 28 29 Angiography, for ocular melanoma, 81 Animal studies, PET for, 71 77 Anorectal melanoma, 85 Antibodies, monoclonal, against melanoma-associated antigens, 91 92 Asymmetry, of lesions, 2 Axilla, sentinel nodes in, 15 B Benzamide compounds, 74 75 Biliary tract, metastasis to, structural imaging for, 39 43 Biopsy, 2, 5. See also Sentinel node biopsy. fine-needle aspiration for recurrent melanoma, 65 ultrasound with, 19 20 Bladder, metastasis to, structural imaging for, 44 46 Bleeding, 2 Blue dye, for intraoperative sentinel node detection, 17 18 Bone, metastasis to MR imaging for, 28 structural imaging for, 49 50 Bone marrow, metastasis to, structural imaging for, 49 50 Borders, of lesions, 2 Boron neutron capture therapy, 93 94 Brachytherapy, for ocular melanoma, 83 Brain melanoma of, 86 metastasis to, 60 MR imaging for, 28 PET/CT for, 32 Breslow depth, 4, 29 PET Clin 6 (2011) 99 103 doi:10.1016/s1556-8598(11)00024-1 1556-8598/11/$ see front matter Ó 2011 Elsevier Inc. All rights reserved. CCMSH compounds, 72, 93 CDKB2A gene, mutations in, 2 Cervical nodes, 15 Chemotherapy for head and neck melanoma, 85 response to, PET/CT for, 31 32 Choroid, melanoma of, 80 83 Ciliary body, melanoma of, 80 Clark level, 4 5 Collaborative Ocular Melanoma Study group, 81 Color, of lesions, 2 Completion lymph node dissection, 10 12 Computed tomography. See CT. Conjunctiva, melanoma of, 80 Contrast agents, for MR imaging, 38 39 Contrast-enhanced CT, for advanced melanoma, 28, 30 Copper 64 compounds, 92 93 CT. See also PET/CT. for adrenal metastasis, 44 for advanced melanoma, 28, 37 54 for biliary tract metastasis, 39 43 for bladder metastasis, 44 46 for bone and bone marrow metastasis, 49 50 for gallbladder metastasis, 39 43 for gastrointestinal metastasis, 46 47 for heart metastasis, 48 49 for kidney metastasis, 44 46 for liver metastasis, 39 43 for lung metastasis, 48 49 for lymph node metastasis, 47 48 for mesentery metastasis, 47 48 for pancreas metastasis, 43 44 for recurrent melanoma, 59 66 for soft tissue metastasis, 49, 51 for spleen metastasis, 43 for ureter metastasis, 44 46 usefulness of, 37 39 whole-body, 44 D [ 18 F]-DAFBA (N-(2-diethylaminoethyl)-4-[ 18 F]- fluorobenzamide), 94 Desmoplastic melanoma, 3 Diameter, of lesions, 2 pet.theclinics.com
100 N-(2-Diethylaminoethyl)-4-[ 18 F]-fluorobenzamide, 94 Diffusion-weighted MR imaging, 38 [ 18 F-]Dopa, 93 DOTA (1,4,7,10-tetraazacyclododecane-1,4,7, 10-tetraacetic acid) compounds, 72 73, 92 93 Dual-time-point imaging PET/CT, 32 Dysplastic nevus syndrome, 2 E Early-stage melanoma, 9 25 sentinel node biopsy in, 9 25 staging of, 5 6, 28 29 Elective lymph node dissection, 9, 84 85 Enucleation, for ocular melanoma, 83 Esophagus, melanoma of, 85 European Association of Nuclear Medicine/European Organization of Research and Treatment of Cancer Committee pathology protocol of, 12 sentinel node biopsy guidelines of, 9 10 Evolution, of lesions, 2 Exteneration, for urogenital melanoma, 85 Eye, melanoma of, 79 89 F Familial multiple mole melanoma, 2 Fatty tissue, metastasis to, structural imaging for, 49, 51 FDG PET for early-stage melanoma, 20 21 for recurrent melanoma, 57, 59 67 PET/CT dual-time-point imaging with, 32 for advanced melanoma, 30 31 for early-stage melanoma, 10, 20 22, 28 29 for follow-up, 31 32 for gastrointestinal melanoma, 85 for meningeal melanoma, 86 for ocular melanoma, 82 83 for recurrent melanoma, 31 32, 59, 61 67 for staging, 28 31 FHBG ([4-[ 18 F]-fluoro-3-(hydroxymethyl)butyl] guanine), 94 Fine-needle aspiration cytology for recurrent melanoma, 65 ultrasound with, 19 20 FLT (3-18 F-fluoro-3 deoxy-l-thymidine), 32, 95 Fluorescein angiography, for ocular melanoma, 81 Fluorobenzamide compounds, 74 75, 94 [ 18 F-]Fluorobenzoate compounds, 73 74, 93 [ 18 F-]Fluorodeoxyglucose. See FDG. 3 -[ 18 F]-Fluoro-3 deoxy-l-thymidine, 32, 95 9-[4-[ 18 F]-Fluoro-3-(hydroxymethyl)butyl]guanine, 94 [ 18 F]-Fluoromisonidazole, 96 Fluoronicotinamide compounds, 74, 94 FMISO ([ 18 F]-fluoromisonidazole), 96 G [ 18 F]-Galacto-arginine-glycine-aspartic acid, 94 95 Gallbladder melanoma of, 85 metastasis to radiography for, 28 structural imaging for, 39 43 Gallium compounds, 72 73, 92 93 Gastrointestinal tract melanoma of, 85 metastasis to, 46 47 Groin, sentinel nodes in, 15 H Head and neck melanoma, sentinel node Heart, metastasis to, structural imaging for, 48 49 Hypoxic cells, tracers for, 95 96 I Indium compounds, 72 73 Indocyanine green angiography, for ocular melanoma, 81 Integrins, as tracers, 94 95 Interval in-transit lymph nodes, 13 14, 18 19 Iris, melanoma of, 80 N-Isopropyl-p-[ 123 I]-iodoamphetamine, 81 82 J John Wayne Cancer Institute protocol, for metastasis pathology, 12 K Kidney, metastasis to, structural imaging for, 44 46 L Lactate dehydrogenase test, 60 Lentigo maligna melanoma, 2 3 Lip, melanoma of, 84 85 Liver, metastasis to radiography for, 28 structural imaging for, 39 43 Local recurrent melanoma, 56, 59 64 Lower extremity, melanoma of, sentinel node
101 Lung, metastasis to PET/CT for, 31 structural imaging for, 48 49 Lymph nodes dissection of completion, 10 12 elective, 9, 84 85 interval in-transit, 13 14, 18 19 metastasis to, 28, 56, 59 64 PET/ 29 structural imaging for, 47 48 sentinel, biopsy of. See Sentinel node biopsy. Lymphadenopathy, 2 Lymphocytes, tumor-infiltrating, 4 Lymphoscintigraphy goals of, 14 importance of, 13 14 inadequate, 12 13 intraoperative, 17 18 procedure for, 14 15 site-specific protocols for, 15 17 M Macrometastases, 12 Magnetic resonance imaging. See MR imaging. [ 18 F-]MEL050, 74 75, 94 Melanin formation, tracers targeting, 93 94 Melanocyte-stimulating hormone analogues, 92 93 a-melanocyte-stimulating hormone peptide analogues, 72 74 Melanocytic lesions, of uncertain malignant potential, sentinel node biopsy for, 19 Melanoma acral-lentiginous, 3 advanced. See Advanced melanoma. amelanotic, 3 animal studies of, 71 77 antigens associated with, 91 92 clinical evaluation of, 2 desmoplastic, 3 diagnosis of, 1 8, 80 81 early-stage. See Early-stage melanoma. epidemiology of, 1 2, 27, 37, 55, 80 extracutaneous, 79 89 familial multiple mole, 2 gastrointestinal, 85 genetic factors in, 2 histology of, 2 5, 80 imaging of, 81 lentigo maligna, 2 3 lifetime risk of, 27 localized, 20, 56, 59 64 meningeal, 86 mucosal, 83 85 nodular, 2 3 ocular, 79 89 pathology of, 2 5 pathophysiology of, 79 80 prognosis for, 2 5, 10 11, 37, 83 84 recurrent. See Recurrent melanoma. staging of. See Staging. subungual, 3 superficial spreading, 2 3 tracers for, 71 77, 91 97. See also FDG. treatment of, 10, 83 failure of, 56 PET/CT for, 31 urogenital, 85 Melanoma Institute of Australia, pathology protocol of, 12 Meningeal melanoma, 86 Mesentery, metastasis to, structural imaging for, 47 48 Metallopeptides, 93 Metastases, 3 5. See also specific sites. common sites of, 27 from head and neck melanoma, 84 85 from ocular melanoma, 81 in staging classification, 28 29 staging of, 12 structural imaging for, 37 54 to sentinel nodes biopsy for. See Sentinel node biopsy. lymphoscintigraphy for, 12 18 visceral, 56, 64 67 Micrometastases, 12 Mitotic rate, 4 5 Monoclonal antibodies, against melanoma-associated antigens, 91 92 Mouth, melanoma of, 84 85 MR imaging for adrenal metastasis, 44 for advanced melanoma, 28, 30, 37 54 for biliary tract metastasis, 39 43 for bladder metastasis, 44 46 for bone and bone marrow metastasis, 49 50 for gallbladder metastasis, 39 43 for gastrointestinal metastasis, 46 47 for heart metastasis, 48 49 for kidney metastasis, 44 46 for liver metastasis, 39 43 for lung metastasis, 48 49 for lymph node metastasis, 47 48 for mesentery metastasis, 47 48 for pancreas metastasis, 43 44 for recurrent melanoma, 59, 66 67 for soft tissue metastasis, 49, 51 for spleen metastasis, 43 for ureter metastasis, 44 46 usefulness of, 37 39 whole-body, 30
102 MSLT-1 (Multicenter Selective Lymphadenectomy Trial 1), 5, 11, 18 Mucosal melanoma, 83 85 Multicenter Selective Lymphadenectomy Trial 1 (MSLT-1), 5, 11, 18 Muscle, metastasis to, 49, 51, 67 N NAPamide compounds, 73 Nasal melanoma, 84 85 National Comprehensive Cancer Network guidelines, for imaging, 59 60 Neck, melanoma of, sentinel node Neoangiogenesis, 94 95 Neurotropism, 4 Nicotinamide analogues, 94 Nodular melanoma, 2 3 O Ocular melanoma, 79 89 diagnosis of, 80 81 epidemiology of, 80 histology of, 80 nuclear medicine for, 81 83 pathophysiology of, 79 80 prognosis for, 83 84 structural imaging for, 81 treatment of, 83 Ophthalmoscopy, for melanoma, 80 81 Oral cavity, melanoma of, 84 85 Ovary, melanoma of, 85 P Pancreas, metastasis to, structural imaging for, 43 44 Paranasal sinuses, melanoma of, 84 85 Penis, melanoma of, 85 PET for early-stage melanoma, 20 21 for recurrent melanoma, 57, 59 67 for staging, 30 small animal, 71 77 tracers for. See Tracers. whole-body, 20, 28 PET/CT for advanced melanoma, 27 35 for early-stage melanoma, 10, 20 22, 28 29 for gastrointestinal melanoma, 85 for meningeal melanoma, 86 for ocular melanoma, 82 83 for recurrent melanoma, 59, 61 67 whole-body, 31, 67 Pharyngolaryngeal melanoma, 84 85 Popliteal nodes, 15 Pregnancy, sentinel node biopsy in, 19 Pruritus, 2 R Radiation therapy for head and neck melanoma, 85 for ocular melanoma, 83 Radiography for advanced melanoma, 28 for ocular melanoma, 81 Radiosurgery, for ocular melanoma, 83 Rectum, melanoma of, 85 Recurrent melanoma, 55 70 evaluation of, 56 59 follow-up for, 59 67 late, 59 local, 56, 59 64 PET/CT for, 31 32 regional, 56, 59 64 risks for, 56 self-detection of, 56 57 sentinel node biopsy and, 18 19 silent spread of, 59 types of, 56 visceral, 56, 64 67 Regional recurrent melanoma, 56, 59 64 Reporter gene imaging, 95 Response Evaluation Criteria in Solid Tumors Working Group, 91 Restaging, 31 32 Rhenium compounds, 72 73, 93 RMSH-1 and RMSH-2, 93 S Sarcophagine chelator, 92 Satellitosis, 5, 56 Sclera, melanoma of, 80 Sentinel node biopsy, 9 25 advantages of, 9 age effects in, 19 conclusions regarding, 20 21 controversial issues in, 18 20 false-negative rate of, 12 13 fine-needle aspiration before, 19 20 for lesions with uncertain malignant potential, 19 for recurrent melanoma, 56, 58 59 in pregnancy, 19 indications for, 11 12 intraoperative dye detection for, 17 18 morbidity from, 11 nuclear medicine with, 13 17 outcome with, 18 overview of, 9 10
103 recurrence rate and, 18 19 staging of, 12 T stage and, 10 ultrasound before, 19 20 versus completion lymph node dissection, 12 Sentinel node status, 4 PET/ 29 prognostic value of, 10 11 Single-photon emission computed tomography. See SPECT. Small intestine, metastasis to, structural imaging for, 46 47 Soft tissue, metastasis to, 49, 51, 67 SPECT for small animal studies, 71 72 SPECT/CT, for early-stage melanoma, 11 15, 17 Spinal cord, metastasis to, MR imaging for, 28 Spleen, metastasis to, structural imaging for, 43 Staging, 3 6 of early melanoma, 5 6 of mucosal melanoma, 84 of ocular melanoma, 81 83 PET/ 31 sentinel node biopsy for, 9 25 Standard uptake value, in recurrent melanoma, 31 Structural imaging, for advanced melanoma, 37 54. See also CT; MR imaging. Subungual melanoma, 3 Sun exposure, 2 Superficial spreading melanoma, 2 3 T Technetium 99m compounds, for sentinel node biopsy, 13 14 1,4,7,10-Tetraazacyclododecane-1,4,7,10- tetraacetic acid (DOTA) compounds, 72 73, 92 93 Thermotherapy, for ocular melanoma, 83 TNM classification, 3 5, 28 29 Tongue, melanoma of, 84 85 Tracers, 91 97. See also FDG. for small animal PET, 71 77 Tremelimumab, 95 Trunk, melanoma of, sentinel node 17 Tumor-infiltrating lymphocytes, 4 Tyrosine, carbon-labeled, 94 U Ugly duckling sign, 2 Ulceration, 3 4 Ultrasound fine-needle aspiration cytology with, 19 20 for advanced melanoma, 28 for recurrent melanoma, 58 59 Upper extremity, melanoma of, sentinel node Ureter, metastasis to, structural imaging for, 44 46 Urethra, melanoma of, 85 Urogenital melanoma, 85 Uterus, melanoma of, 85 Uvea, melanoma of, 80, 83 V Vagina, melanoma of, 85 Visceral recurrent melanoma, 56, 64 67 Vulva, melanoma of, 85 W Whole-body CT, for ocular melanoma, 81 Whole-body MR imaging, for advanced melanoma, 30 Whole-body PET, for staging, 20, 28 Whole-body PET/CT for advanced melanoma, 31 for recurrent melanoma, 67 Y Yttrium compounds, 72, 93